SCHEDULE: CVI Investments Discloses 9.9% Stake in Pasithea

CVI Investments and Heights Capital Management report a 9.9% passive beneficial ownership stake in Pasithea Therapeutics Corp. common stock.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') have filed an Amendment No. 1 to Schedule 13G.
• The Reporting Persons collectively beneficially own 826,145 shares of Pasithea Therapeutics Corp. common stock.
• This ownership represents 9.9% of the company's outstanding common stock.
• The shares beneficially owned consist of shares issuable upon the exercise of Series C Common Warrants and Series D Common Warrants.
• The warrants are subject to a blocker provision, preventing exercise if beneficial ownership would exceed 9.99%.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and may exercise voting and dispositive power over the reported shares.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, indicating a passive investment.

Sentiment

Score: 7

Explanation: The filing indicates a significant, albeit passive, institutional investment in Pasithea Therapeutics Corp., which can be viewed as a positive signal of investor confidence. However, it is a routine ownership disclosure and does not contain performance or operational updates.

Positives

• A significant institutional investor, CVI Investments, Inc., holds a substantial 9.9% stake, potentially signaling confidence in Pasithea Therapeutics Corp.
• The investment is passive, indicating no immediate intent to influence or change company control, which can provide stability.

Negatives

• NA

Risks

• The beneficial ownership is primarily through warrants, which may introduce dilution risk upon exercise if not already factored into the market price.
• The 9.99% exercise limitation on warrants means the investor cannot easily increase their stake beyond this threshold without further disclosures or changes.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Pasithea Therapeutics Corp., a company operating in the biotechnology or pharmaceutical sector. Such disclosures are common for publicly traded companies as institutional investors adjust their holdings.

Comparison to Industry Standards

• A 9.9% passive stake by an investment firm like CVI Investments is a significant position, often seen in smaller-cap biotechnology companies where institutional support can be crucial.
• The use of warrants for beneficial ownership is a common financing mechanism in the biotech industry, allowing investors to gain exposure with potential for future equity conversion.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may influence market perception and liquidity.
• Company Management: Awareness of a large passive investor may influence strategic decisions, though the filing explicitly states no intent to control.

Key Dates

Keywords

Pasithea Therapeutics, CVI Investments, Heights Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals